Eli Lilly is going for it again, inking $2B Alzheimer’s deal for tau therapies with AC Immune

No biopharma company has suffered as many clinical setbacks in Alzheimer’s drug research as Eli Lilly. But that hasn’t stopped the pharma giant from driving back toward the clinic with a deal worth close to $2 billion for a portfolio of preclinical tau aggregation inhibitors.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,100+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->